Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Tuesday, October 15, 2024
Tag: 2.6B
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.